In addition, this drug combination may be tested as a frontline therapy to potentially delay the development of osimertinib resistance and increase the durability of response to frontline therapy of EGFR mutant lung cancer that needs to be tested in pre-clinical models and subsequently in clinical studies. Here, EGFR is linked to lung carcinoma.